Silver Lake Enters Into Exclusive Negotiations to Acquire Groupe Meilleurtaux
22.7.2020 21:49:00 EEST | Business Wire | Press release
Groupe Meilleurtaux (“the Company”), a leading French financial services provider, Silver Lake, a global technology investment firm, and West Street Capital Partners VII (a fund managed by the Goldman Sachs Merchant Banking Division), today announced that they have entered into exclusive negotiations under which Silver Lake would acquire a majority stake in Groupe Meilleurtaux from West Street Capital Partners VII. Management would re-invest in Meilleurtaux alongside Silver Lake.
Hervé Hatt and Guillaume Autier, Chairman and CEO of Groupe Meilleurtaux, said: “We are extremely proud of what Meilleurtaux has achieved over the past three years, with the group’s revenue doubling between 2017 and 2019. Together with our outstanding team, our franchisees, and our partners, we have built a highly successful business with a strong track record of increasing transparency and access to the French financial services ecosystem. As Meilleurtaux begins its new chapter of growth, we are thrilled to welcome Silver Lake, a world-class technology investor with deep financial services and online industry expertise as well as strong value-creation capabilities, as our new majority investor. This investment marks a pivotal step for our company, and we are excited to lead it through this journey.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Meilleurtaux is an exceptional company with a unique value proposition across its ecosystem of customers, channel partners and financial providers. We are highly impressed by the way Hervé, Guillaume and the rest of the team have strengthened the business and built it into a multi-channel financial services powerhouse with some 90 million online and mobile visits per year across its various properties. Investing in high-growth, impactful and pioneering business models is at the core of Silver Lake’s DNA, and the privilege of partnering with this management team as Meilleurtaux enters a new phase of growth and value creation is firmly consistent with our mission.”
Michele Titi-Cappelli, Managing Director and Alexandre Flavier, Executive Director of Goldman Sachs, added: “Meilleurtaux is an outstanding platform that plays a pivotal role in democratizing transparency and consumer choice in the French financial services ecosystem. We couldn’t be more pleased with the success of Meilleurtaux under the leadership of Hervé, Guillaume and their team since 2017. We strongly believe that Meilleurtaux is still at the beginning of its growth journey.”
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux provides a broad and diversified range of financial services and products that started historically with mortgage loan comparison and brokerage. Its wide suite of high-quality solutions is seamlessly accessible to consumers through a comprehensive range of leading online and mobile tools including its flagship websites Meilleurtaux.com, Lecomparateurassurance.com and Meilleurplacement.com, as well as financial information website MoneyVox, which in aggregate attract an industry-leading number of approximately 90 million yearly visits. Meilleurtaux.com’s award winning and web-native digital solutions comprise a set of innovative, client-centric toolkits including intuitive financial simulators, calculators and barometers focused solely on helping households save money across their most important financial life decisions on a daily basis. The Company’s unique multi-channel offering is enabled by France’s largest network of 340 brokerage branches, offering customers an unmatched service level in partnership with an industry leading network of more than 300 established bank and insurance providers that together have shaped Meilleurtaux’s trusted brand for over two decades.
Silver Lake is planning to invest heavily in Groupe Meilleurtaux’s product range and partnership network to help further accelerate the Company’s strong organic and inorganic revenue growth across its core business of mortgage and loan insurance brokerage, as well as to further expand its leading offering across the financial services ecosystem. Silver Lake will thereby preserve Groupe Meilleurtaux’s winning operating model while leveraging its capabilities to support management in strengthening it further.
The proposed transaction is expected to close in the fourth quarter and is subject to regulatory approvals and works council information and consultation procedures.
From 1 August 2020 the Meilleurtaux Group’s leadership team will include Guillaume Autier as CEO and Thomas Kienzi as CFO, with Hervé Hatt as chairman of the Board.
About Groupe Meilleurtaux and Meilleurtaux.com
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux is a leading French financial services provider with a broad and diversified range of financial services including loan insurance and mortgage brokerage, debt consolidation solutions, savings & investment products as well as P&C and health insurance distribution and brokerage offerings, available both online and through France’s largest network of 340 brokerage branches. For more information, please visit meilleurtaux.com
About Silver Lake
Silver Lake is a global technology investment firm, with over $40 billion in combined assets under management and committed capital and a team of approximately 100 investment and operating professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of investments collectively generates more than $230 billion of revenue annually and employs 370,000 people globally. For more information about Silver Lake and its portfolio, please visit silverlake.com.
About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005830/en/
Contact information
Media contacts
FOR SILVER LAKE:
Jennifer Stroud
jennifer.stroud@edelman.com
M: +1-646-565-1792
Virginie Spelle
virginie.spelle@elanedelman.com
M: +33 (0)6 34 03 15 00
FOR GOLDMAN SACHS MERCHANT BANKING DIVISION:
Joseph Stein
+44 20 7774 2523
FOR MEILLEURTAUX.COM:
Anne-Charlotte Neau
anne-charlotte.neau@taddeo.fr
+33(0)6 23 73 56 03
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom